ADC is Back: Why CDH17 This Time?
Recently, the biopharmaceutical sector seems to be reviving. Perhaps the BD departments of MNCs have returned from their summer breaks, reigniting the cross-ocean BD wave. On October 17, Hansoh Pharmaceutical announced a licensing collaboration with global oncology giant Roche for its CDH17 ADC new drug HS-20110. Roche will pay 80 million USD as an upfront … Read more
